Inclusion Criteria:

- Male patients with a diagnosis of advanced prostate cancer for whom treatment with
triptorelin pamoate or leuprolide acetate is indicated;

- At least 18 years of age;

- Life expectancy of at least 1 year;

- Capable of completing the study questionnaires without assistance.

Exclusion Criteria:

- Patients for whom treatment with triptorelin pamoate or leuprolide acetate is
contraindicated;

- Known hypersensitivity to triptorelin, leuprolide or any other GnRH or luteinizing
hormone releasing hormone (LHRH) agonists, or GnRH or LHRH;

- Clinically significant systemic disease or condition that would, in the
investigator's opinion, lead to undue risk following administration of either
triptorelin or leuprolide;

- History of alcohol/drug abuse within the past year;

- History of significant medical problems that may confound the outcome of this study;

- Requires concomitant medications that may affect study assessments (e.g., topical
medications used for pretreatment of injection site pain);

- Participated in another investigational drug study within 30 days

- Judged by the investigator to be unsuitable for enrollment in this study for any
reason